# (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

> **NCT02508532** · PHASE1 · COMPLETED · sponsor: **Blueprint Medicines Corporation** · enrollment: 250 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors (GIST)
- Other Relapsed or Refractory Solid Tumors

## Interventions

- **DRUG:** Avapritinib

## Key facts

- **NCT ID:** NCT02508532
- **Lead sponsor:** Blueprint Medicines Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2020-03-06
- **Final completion:** 2021-06-03
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508532, "(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02508532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*